Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Estradiol 3-phosphate controlled-release - Redwood Pharma

Drug Profile

Estradiol 3-phosphate controlled-release - Redwood Pharma

Alternative Names: 17beta-Estradiol-3-phosphate; Estradiol, 3-(dihydrogen phosphate); Estradiol-3-phosphate; RP101 - Redwood Pharma

Latest Information Update: 25 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Redwood Pharma
  • Class Estradiol congeners; Eye disorder therapies; Hormonal replacements; Small molecules
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Dry eyes

Highest Development Phases

  • Phase II Dry eyes

Most Recent Events

  • 25 Jul 2022 No development reported - Phase-II for Dry eyes (In children, In the elderly, In adults) in Hungary, Germany, Austria (Ophthalmic)
  • 22 Mar 2021 Safety and efficacy data from phase II trial in Dry eye disease released by Redwood Pharma
  • 28 Dec 2020 Efficacy data from a phase II trial in Dry eyes released by Redwood Pharma
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top